Hospital-Acquired Infections Market to Reach USD 19.5 Billion by 2030 | CAGR 3.8% | North America Leads with 40% Share | Key Players: Pfizer, Roche, AbbVie, AstraZeneca, GSK

Market Overview

The Global Hospital Acquired Infections (HAIs) Market reached USD 14.4 billion in 2022 and is projected to grow steadily, reaching USD 19.5 billion by 2030, at a CAGR of 3.8% during the forecast period 2023-2030. The market expansion is driven by the rising prevalence of infectious diseases such as pneumonia, bloodstream infections, surgical site infections, and urinary tract infections, along with the increasing need for infection prevention and control measures in healthcare settings.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/hospital-acquired-infections-market?Juli

Hospital-acquired infections (HAIs), also known as nosocomial infections, refer to infections that develop during hospital stays or within healthcare facilities, typically appearing 48 hours or more after admission. These infections are a growing global concern due to the rising patient population, extended hospital stays, and the widespread use of invasive medical devices. The market is witnessing robust growth due to rising regulatory approvals for anti-infective drugs, increased research and development in antimicrobial resistance (AMR), and the introduction of advanced sterilization and disinfection technologies. Moreover, the growing emphasis on infection surveillance systems, combined with AI-based hospital hygiene management, is transforming infection control protocols globally.

Recent Developments:

✅ December 2025: A major pharmaceutical company launched a next-generation anti-infective therapy targeting multi-drug resistant hospital pathogens, with improved efficacy against common HAI organisms like MRSA and Pseudomonas.

✅ October 2025: A global biotech firm received regulatory approval for a rapid point-of-care diagnostic test that identifies bloodstream infection pathogens and antibiotic resistance markers within hours, significantly reducing time to targeted treatment.

✅ August 2025: Several leading hospitals in North America and Europe implemented AI-enabled infection surveillance platforms that analyze electronic health records and patient flow data to predict and prevent outbreak clusters in real time.

✅ June 2025: A collaborative initiative between academic centers and diagnostics manufacturers expanded clinical trials for novel antimicrobial coatings on catheters and surgical implants to reduce device-associated HAIs.

✅ April 2025: A major healthcare provider deployed automated UV-C and robotics-assisted room disinfection systems across its network, resulting in measurable reductions in key hospital-acquired infection rates in pilot facilities.

Mergers & Acquisitions:

✅ November 2025: A leading anti-infective drug manufacturer acquired a specialized diagnostics firm focused on rapid pathogen identification to integrate point-of-care testing with its HAI treatment portfolio.

✅ September 2025: A global pharmaceutical company completed the acquisition of a biotech startup developing novel antimicrobial peptides, strengthening its pipeline against drug-resistant HAI pathogens.

✅ July 2025: A major infection prevention solutions provider acquired a hospital hygiene automation technology company to expand its portfolio of robotics-assisted disinfection and surveillance systems.

✅ May 2025: A multinational healthcare corporation acquired a clinical microbiome analytics firm to enhance its capabilities in identifying microbiome-based risk factors for HAIs and tailoring preventive interventions.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=hospital-acquired-infections-market?Juli

Key Players:
Pfizer | Roche | AbbVie | AstraZeneca | GSK | Innoviva | Eli Lilly | Cipla | Basilea Pharmaceutica

Key Highlights:

Pfizer - Holds an estimated 16% market share, driven by its broad anti-infective portfolio including Zyvox (linezolid) and Zosyn (piperacillin/tazobactam), as well as new developments in combating multi-drug resistant Gram-positive and Gram-negative pathogens.

Roche - Holds around 13%, leveraging its strengths in diagnostics and antimicrobial research. The company's advanced diagnostic platforms and collaborations in infection surveillance have strengthened its presence in HAI detection and management.

AbbVie - Accounts for approximately 11%, focusing on novel antibiotic-resistant infection treatments and combination therapies targeting respiratory and bloodstream infections commonly associated with hospital settings.

AstraZeneca - Holds 10%, emphasizing the development of beta-lactamase inhibitor combinations and next-generation antibiotics targeting severe hospital infections, especially ventilator-associated pneumonia and sepsis.

GSK (GlaxoSmithKline) - Represents 9%, driven by its antimicrobial R&D collaborations and strong legacy portfolio of hospital anti-infective drugs, along with ongoing efforts to develop treatments for resistant Gram-negative bacteria.

Innoviva - Holds 8%, supported by its partnership network developing novel inhaled and systemic anti-infectives. The company's focus on next-generation antibiotics positions it as a rising player in the HAI therapeutics space.

Eli Lilly - Holds 8%, contributing through its broad-spectrum antibiotic developments, critical care solutions, and ongoing clinical trials addressing sepsis and bloodstream infections.

Cipla - Accounts for about 7%, leading in generic and affordable anti-infective solutions, particularly in emerging markets. The company continues to invest in hospital antibiotic formulations and infection prevention products.

Basilea Pharmaceutica - Holds 6%, specializing in innovative anti-infectives like ceftobiprole and isavuconazole, designed to treat serious hospital-acquired infections including MRSA and fungal infections in immunocompromised patients.

Market Segmentation:

By Infection Type:
Ventilator-Associated Pneumonia (VAP) leads the market with approximately 28% share, driven by the high prevalence of respiratory infections among ICU patients requiring mechanical ventilation. VAP remains one of the most fatal hospital-acquired infections, fueling demand for advanced antibiotics and infection prevention systems. Urinary Tract Infections (UTIs) account for 22%, primarily due to catheter-associated infections and extended hospital stays. Surgical Site Infections (SSIs) hold around 20%, supported by the increasing number of surgeries and the need for sterilization and post-operative care solutions. Bloodstream Infections (BSIs) represent 15%, as cases linked to central line usage and invasive procedures continue to rise. Gastrointestinal Infections, including Clostridium difficile and norovirus, contribute 10%, while other HAIs-such as skin, wound, and soft-tissue infections-make up the remaining 5%.

By End User:
Hospitals & Intensive Care Units (ICUs) dominate the market, holding approximately 55% share, as these facilities report the highest rate of nosocomial infections due to high patient density, invasive treatments, and prolonged admissions. Ambulatory Surgical & Diagnostic Centers follow with 20%, supported by growing outpatient surgeries and the need for strict infection control standards. Nursing Homes & Maternity Centers account for 15%, reflecting the increasing number of elderly and immunocompromised patients prone to HAIs. The remaining 10% is attributed to other healthcare facilities, including specialty clinics and rehabilitation centers that face rising infection management demands.

By Drug Type:
Antibacterial drugs dominate with a 60% market share, given their central role in treating common hospital-acquired bacterial infections such as pneumonia, UTIs, and BSIs. Antifungal drugs hold 20%, targeting invasive fungal infections, particularly in immunocompromised or post-surgical patients. Antiviral drugs represent 10%, used to manage infections caused by pathogens like influenza or cytomegalovirus in hospital settings. The remaining 10% includes other therapeutics, such as antiseptics and immunotherapies used as adjunctive treatments in infection prevention and control.

By Distribution Channel:
Hospital Pharmacies lead with around 50% share, reflecting the dominance of inpatient treatments and direct drug procurement by healthcare institutions. Retail Pharmacies hold approximately 30%, supported by outpatient prescriptions and follow-up infection management. Online Pharmacies are gaining traction, representing 20%, as digital health platforms expand access to anti-infective medications, especially in developed markets with advanced e-pharmacy ecosystems.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/hospital-acquired-infections-market?Juli

Regional Insights:

North America dominates the global hospital-acquired infections market, accounting for approximately 40% of total revenue. The region's leadership is attributed to advanced healthcare infrastructure, stringent infection control regulations, and the presence of major pharmaceutical players such as Pfizer, AbbVie, and Innoviva. The U.S. alone accounts for the majority share within North America, supported by high hospital admission rates, increased awareness of HAIs, and strong government initiatives such as the Centers for Disease Control and Prevention (CDC)'s Hospital Infection Control Program. Furthermore, widespread adoption of antimicrobial stewardship programs and AI-enabled infection surveillance tools continues to drive market growth.

Europe holds around 27% of the market share, with leading countries including Germany, the UK, France, and Italy focusing heavily on infection prevention protocols, regulatory compliance, and hospital hygiene programs. The European Centre for Disease Prevention and Control (ECDC) initiatives, coupled with strong R&D activity in antimicrobial resistance management, are boosting the regional market. Investments in advanced diagnostic tools and hospital disinfection technologies are also reinforcing Europe's position in the global market.

Asia-Pacific (APAC) represents approximately 22% of the global market and is expected to witness the fastest growth during the forecast period. Rising hospitalization rates, expanding healthcare infrastructure, and increasing awareness about hospital hygiene and infection control are fueling market expansion in countries like China, India, Japan, and South Korea. Additionally, government-led healthcare reforms and partnerships with international health organizations are improving infection surveillance and treatment accessibility across the region.

Market Dynamics:

Driver: Rising Incidence of Hospital-Acquired Infections Fueling Market Growth
The global hospital-acquired infections (HAIs) market is being driven by the rising incidence of infections in healthcare settings, coupled with an increasing demand for effective treatment at the point of care. The growing prevalence of chronic diseases has led to a surge in hospital admissions, subsequently increasing the risk of HAIs among vulnerable patients. According to StatPearls (2022), factors such as immunosuppression, prolonged hospital stays, advanced patient age, multiple comorbidities, mechanical ventilation, invasive surgeries, and the use of indwelling medical devices significantly elevate infection risk.

Hospitalization, though essential for managing acute conditions, often exposes patients to antibiotic-resistant microorganisms. As a result, hospitals are prioritizing infection prevention by adopting infection surveillance systems, antimicrobial stewardship programs, and data-driven prevention strategies. These initiatives are aimed at reducing nosocomial infection rates while maintaining compliance with global infection control standards.

Furthermore, the increasing focus on AI-based infection tracking, robotic disinfection systems, and rapid diagnostic tools is revolutionizing infection management, thereby supporting overall market growth. The convergence of digital health and infection prevention technologies is expected to accelerate the adoption of next-generation solutions across hospitals and intensive care units globally.

Opportunity:
The market is witnessing significant opportunities driven by regulatory approvals for innovative anti-infective drugs and the launch of novel therapeutic products targeting antibiotic-resistant pathogens. Leading pharmaceutical companies are investing in the development of next-generation antimicrobials, vaccines, and diagnostics that address critical unmet needs in infection control.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.